Advantages of nanomedicine over the conventional treatment in Acute myeloid leukemia

Janani, Gopalarethinam; Girigoswami, Agnishwar; Girigoswami, Koyeli

doi:10.1080/09205063.2023.2294541

Cited by 3 publications

(1 citation statement)

References 147 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No delayed hatching was observed in the treatment groups, and the findings were similar to those of the control group. Nanomedicines have the property of enhancing biocompatibility, and they are target specific [29]. These results show that both HA and NHA have no teratogenic effect and are biocompatible up to a dose of 100 µg/mL.…”

Section: In Vivo Toxicity Studymentioning

confidence: 68%

Unveiling the Role of Nano-Formulated Red Algae Extract in Cancer Management

Janani,

Girigoswami,

Deepika

et al. 2024

Molecules

Self Cite

View full text Add to dashboard Cite

Cancer is one of the major causes of death, and its negative impact continues to rise globally. Chemotherapy, which is the most common therapy, has several limitations due to its tremendous side effects. Therefore, developing an alternate therapeutic agent with high biocompatibility is indeed needed. The anti-oxidative effects and bioactivities of several different crude extracts of marine algae have been evaluated both in vitro and in vivo. In the present study, we synthesized the aqueous extract (HA) from the marine algae Amphiroa anceps, and then, a liposome was formulated for that extract (NHA). The extracts were characterized using different photophysical tools like dynamic light scattering, UV–visible spectroscopy, FTIR, scanning electron microscopy, and GC-MS analysis. The SEM image revealed a size range of 112–185 nm for NHA and the GC-MS results showed the presence of octadecanoic acid and n-Hexadecanoic acid in the majority. The anticancer activity was studied using A549 cells, and the NHA inhibited the cancer cells dose-dependently, with the highest killing of 92% at 100 μg/mL. The in vivo studies in the zebrafish model showed that neither the HA nor NHA of Amphiroa anceps showed any teratogenic effect. The outcome of our study showed that NHA can be a potential drug candidate for inhibiting cancer with good biocompatibility up to a dose of 100 μg/mL.

show abstract

Section: In Vivo Toxicity Studymentioning

confidence: 68%